94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Med.
Sec. Ophthalmology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1527319
This article is part of the Research Topic Reviews in: Ophthalmology 2024 View all 5 articles
Challenging Glaucoma with Emerging Therapies: An Overview of Advancements against the Silent Vision Thief
Provisionally accepted- 1 Institute of Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
- 2 Université de Montpellier, Montpellier, Languedoc-Roussillon, France
- 3 Théa Laboratories, Clermont-Ferrand, France
- 4 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
Glaucoma, a leading cause of irreversible blindness, represents a significant challenge in ophthalmology. This review examines recent advancements in glaucoma treatment, focusing on innovative medications and creative strategies. While new agents offer promising methods for lowering intraocular pressure (IOP), they also pose challenges related to efficacy and side effects. Alongside IOP reduction, emerging neuroprotective approaches are being explored to safeguard retinal ganglion cells (RGCs) from glaucoma-induced damage. The review also evaluates the potential of novel drug delivery systems, such as biodegradable implants and nanoparticles, to enhance treatment effectiveness and patient adherence. Additionally, it highlights the role of personalized medicine in identifying new biomarkers and customizing therapies based on individual genetic and environmental factors.
Keywords: Glaucoma, Intraocular Pressure, Neuroprotection, Innovative treatments, Gene Therapy
Received: 13 Nov 2024; Accepted: 07 Mar 2025.
Copyright: © 2025 Sarkis, Chamard, Johansen, Daien and Michon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Frederic Michon, Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, 00014, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.